John Dibato1, Olga Montvida1, Joanna Ling1, Digsu Koye1, William H Polonsky2, Sanjoy K Paul3,4. 1. Melbourne EpiCentre, Department of Medicine at Royal Melbourne Hospital, University of Melbourne, Melbourne, VIC, Australia. 2. Department of Family and Community Medicine, University of California, San Diego, CA, USA. 3. Melbourne EpiCentre, Department of Medicine at Royal Melbourne Hospital, University of Melbourne, Melbourne, VIC, Australia. sambhupaul@hotmail.com. 4. AstraZeneca, London, UK. sambhupaul@hotmail.com.
Abstract
AIMS/HYPOTHESIS: We aimed to investigate the prevalence and incidence of depression, and the interplay of cardiometabolic comorbidities, in the differentiation of depression risk between young-onset diabetes (diagnosis at age <40 years) and usual-onset diabetes (diagnosis at age ≥40 years). METHODS: Using electronic medical records from the UK and USA, retrospective cohorts of adults with incident type 2 diabetes diagnosed between 2006 and 2017 were examined. Trends in the prevalence and incidence of depression, and risk of developing depression, in participants with young-onset type 2 diabetes compared with usual-onset type 2 diabetes were assessed separately by sex and comorbidity status. RESULTS: In total 230,932/1,143,122 people with type 2 diabetes from the UK/USA (mean age 58/60 years, proportion of men 57%/46%) were examined. The prevalence of depression in the UK/USA increased from 29% (95% CI 28, 30)/22% (95% CI 21, 23) in 2006 to 43% (95% CI 42, 44)/29% (95% CI 28, 29) in 2017, with the prevalence being similar across all age groups. A similar increasing trend was observed for incidence rates. In the UK, compared with people aged ≥50 years with or without comorbidity, 18-39-year-old men and women had 23-57% and 20-55% significantly higher risks of depression, respectively. In the USA, compared with those aged ≥60 years with or without comorbidity, 18-39-year-old men and women had 5-17% and 8-37% significantly higher risks of depression, respectively. CONCLUSIONS/ INTERPRETATION: Depression risk has been increasing in people with incident type 2 diabetes in the UK and USA, particularly among those with young-onset type 2 diabetes, irrespective of other comorbidities. This suggests that proactive mental health assessment from the time of type 2 diabetes diagnosis in primary care is essential for effective clinical management of people with type 2 diabetes.
AIMS/HYPOTHESIS: We aimed to investigate the prevalence and incidence of depression, and the interplay of cardiometabolic comorbidities, in the differentiation of depression risk between young-onset diabetes (diagnosis at age <40 years) and usual-onset diabetes (diagnosis at age ≥40 years). METHODS: Using electronic medical records from the UK and USA, retrospective cohorts of adults with incident type 2 diabetes diagnosed between 2006 and 2017 were examined. Trends in the prevalence and incidence of depression, and risk of developing depression, in participants with young-onset type 2 diabetes compared with usual-onset type 2 diabetes were assessed separately by sex and comorbidity status. RESULTS: In total 230,932/1,143,122 people with type 2 diabetes from the UK/USA (mean age 58/60 years, proportion of men 57%/46%) were examined. The prevalence of depression in the UK/USA increased from 29% (95% CI 28, 30)/22% (95% CI 21, 23) in 2006 to 43% (95% CI 42, 44)/29% (95% CI 28, 29) in 2017, with the prevalence being similar across all age groups. A similar increasing trend was observed for incidence rates. In the UK, compared with people aged ≥50 years with or without comorbidity, 18-39-year-old men and women had 23-57% and 20-55% significantly higher risks of depression, respectively. In the USA, compared with those aged ≥60 years with or without comorbidity, 18-39-year-old men and women had 5-17% and 8-37% significantly higher risks of depression, respectively. CONCLUSIONS/ INTERPRETATION: Depression risk has been increasing in people with incident type 2 diabetes in the UK and USA, particularly among those with young-onset type 2 diabetes, irrespective of other comorbidities. This suggests that proactive mental health assessment from the time of type 2 diabetes diagnosis in primary care is essential for effective clinical management of people with type 2 diabetes.
Authors: Digsu N Koye; Joanna Ling; John Dibato; Kamlesh Khunti; Olga Montvida; Sanjoy K Paul Journal: Diabetes Care Date: 2020-07-02 Impact factor: 19.112
Authors: Dianna J Magliano; Lei Chen; Rakibul M Islam; Bendix Carstensen; Edward W Gregg; Meda E Pavkov; Linda J Andes; Ran Balicer; Marta Baviera; Elise Boersma-van Dam; Gillian L Booth; Juliana C N Chan; Yi Xian Chua; Sandrine Fosse-Edorh; Sonsoles Fuentes; Hanne L Gulseth; Romualdas Gurevicius; Kyoung Hwa Ha; Thomas R Hird; György Jermendy; Mykola D Khalangot; Dae Jung Kim; Zoltán Kiss; Victor I Kravchenko; Maya Leventer-Roberts; Chun-Yi Lin; Andrea O Y Luk; Manel Mata-Cases; Didac Mauricio; Gregory A Nichols; Mark M Nielen; Deanette Pang; Sanjoy K Paul; Catherine Pelletier; Santa Pildava; Avi Porath; Stephanie H Read; Maria Carla Roncaglioni; Paz Lopez-Doriga Ruiz; Marina Shestakova; Olga Vikulova; Kang-Ling Wang; Sarah H Wild; Naama Yekutiel; Jonathan E Shaw Journal: Lancet Diabetes Endocrinol Date: 2021-02-23 Impact factor: 32.069
Authors: Calvin Ke; Eric Lau; Baiju R Shah; Thérèse A Stukel; Ronald C Ma; Wing-Yee So; Alice P Kong; Elaine Chow; Philip Clarke; William Goggins; Juliana C N Chan; Andrea Luk Journal: Ann Intern Med Date: 2019-01-15 Impact factor: 25.391
Authors: John Epoh Dibato; Olga Montvida; Francesco Zaccardi; Jack Alistair Sargeant; Melanie J Davies; Kamlesh Khunti; Sanjoy K Paul Journal: Diabetes Care Date: 2020-11-11 Impact factor: 19.112
Authors: Dianna J Magliano; Julian W Sacre; Jessica L Harding; Edward W Gregg; Paul Z Zimmet; Jonathan E Shaw Journal: Nat Rev Endocrinol Date: 2020-03-20 Impact factor: 43.330